Printed From:

FOR US RESIDENTS ONLY

FOR US RESIDENTS ONLY

Important Safety Information

Prescribing Information

Patient Information

US Healthcare Professionals Site

Home
How
sarclisa Works
Clinical
Trial Results
- Possible Side Effects
- How sarclisa Is Given
- Paying for sarclisa
- Patient and Caregiver
  Resources

Important Safety Information Prescribing Information Patient Information US Healthcare Professionals Site

FOR ADULTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA

Learn more

Site Map

How SARCLISA Works

Clinical Trial Results

SARCLISA Treatment

Possible Side Effects
How SARCLISA Is Given

Living With Multiple Myeloma

Patient and Caregiver Stories
About Previously Treated
Multiple Myeloma
FAQs

Financial Resources and Support

Paying for SARCLISA
Patient and Caregiver Resources

Important Safety Information

Do not receive SARCLISA if you have a history of a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in the full Prescribing Information).

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

Have heart problems, if your healthcare provider prescribes SARCLISA in combination with carfilzomib and dexamethasone for you.
Are pregnant or plan to become pregnant. SARCLISA may harm your unborn baby. You should not receive SARCLISA during pregnancy.
- — Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.
Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.
Are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. You should not breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines. Especially tell your healthcare provider if you have ever taken a medicine for your heart.

How will I receive SARCLISA?

SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
SARCLISA is given in treatment cycles of 28 days (4 weeks), together with either the medicines pomalidomide and dexamethasone, or carfilzomib and dexamethasone.
- — In cycle 1, SARCLISA is usually given weekly.
- — Starting in cycle 2, SARCLISA is usually given every 2 weeks.
If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
Your healthcare provider will give you medicines before each dose of SARCLISA to help reduce the risk of infusion reactions (make them less frequent and severe).

What are the possible side effects of SARCLISA?

SARCLISA may cause serious side effects, including:

Infusion reactions. Infusion reactions are common with SARCLISA and can sometimes be severe or life threatening.
- — Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.
- — Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA if you have an infusion reaction.
Get medical help right away if you develop any of the following symptoms of infusion reaction during or after an infusion of SARCLISA:
- — shortness of breath, wheezing, or trouble breathing
- — swelling of the face, mouth, throat, or tongue
- — throat tightness
- — palpitations
- — dizziness, lightheadedness, or fainting
- — headache
- — cough
- — rash or itching
- — nausea
- — runny or stuffy nose
- — chills
Decreased white blood cell counts. Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. You may have an increased risk of getting certain infections, such as upper and lower respiratory tract infections and urinary tract infections.

Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.

Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.

Risk of new cancers. New cancers have happened in people during treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.
Change in blood tests. SARCLISA can affect the results of blood tests to match your blood type. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.
Heart failure. Heart failure can happen during treatment with SARCLISA in combination with carfilzomib and dexamethasone. Tell your healthcare provider right away if you develop any of the following symptoms:
- — trouble breathing
- — cough
- — swelling of your ankles, feet, or legs

The most common side effects of SARCLISA in combination with pomalidomide and dexamethasone include:

lung infection (pneumonia)
decreased red blood cell counts (anemia)
upper respiratory tract infection
decreased platelet counts (thrombocytopenia)
diarrhea

The most common side effects of SARCLISA in combination with carfilzomib and dexamethasone include:

upper respiratory tract infection
tiredness and weakness
high blood pressure
diarrhea
lung infection (pneumonia)
trouble breathing
trouble sleeping
bronchitis
cough
back pain
decreased red blood cells (anemia)
decreased platelet counts (thrombocytopenia)

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

Please see full Prescribing Information, including Patient Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

What is SARCLISA?

SARCLISA is a prescription medicine used in combination with:

The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment and they did not work or are no longer working.

It is not known if SARCLISA is safe and effective in children.

Please see full Prescribing Information, including Patient Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Important Safety Information

Do not receive SARCLISA if you have a history of a severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in the full Prescribing Information).

Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:

Have heart problems, if your healthcare provider prescribes SARCLISA in combination with carfilzomib and dexamethasone for you.
Are pregnant or plan to become pregnant. SARCLISA may harm your unborn baby. You should not receive SARCLISA during pregnancy.
- — Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose of SARCLISA. Talk to your healthcare provider about birth control methods that you can use during this time.
Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.
Are breastfeeding or plan to breastfeed. It is not known if SARCLISA passes into your breast milk. You should not breastfeed during treatment with SARCLISA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines. Especially tell your healthcare provider if you have ever taken a medicine for your heart.

How will I receive SARCLISA?

SARCLISA will be given to you by your healthcare provider by intravenous (IV) infusion into your vein.
SARCLISA is given in treatment cycles of 28 days (4 weeks), together with either the medicines pomalidomide and dexamethasone, or carfilzomib and dexamethasone.
- — In cycle 1, SARCLISA is usually given weekly.
- — Starting in cycle 2, SARCLISA is usually given every 2 weeks.
If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
Your healthcare provider will give you medicines before each dose of SARCLISA to help reduce the risk of infusion reactions (make them less frequent and severe).

What are the possible side effects of SARCLISA?

SARCLISA may cause serious side effects, including:

Infusion reactions. Infusion reactions are common with SARCLISA and can sometimes be severe or life threatening.
- — Your healthcare provider will prescribe medicines before each infusion of SARCLISA to help decrease your risk for infusion reactions or to help make any infusion reaction less severe. You will be monitored for infusion reactions during each dose of SARCLISA.
- — Your healthcare provider may slow down or stop your infusion, or completely stop treatment with SARCLISA if you have an infusion reaction.
Get medical help right away if you develop any of the following symptoms of infusion reaction during or after an infusion of SARCLISA:
- — shortness of breath, wheezing, or trouble breathing
- — swelling of the face, mouth, throat, or tongue
- — throat tightness
- — palpitations
- — dizziness, lightheadedness, or fainting
- — headache
- — cough
- — rash or itching
- — nausea
- — runny or stuffy nose
- — chills
Decreased white blood cell counts. Decreased white blood cell counts are common with SARCLISA and certain white blood cells can be severely decreased. You may have an increased risk of getting certain infections, such as upper and lower respiratory tract infections and urinary tract infections.

Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA.

Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.

Risk of new cancers. New cancers have happened in people during treatment with SARCLISA. Your healthcare provider will monitor you for new cancers during treatment with SARCLISA.
Change in blood tests. SARCLISA can affect the results of blood tests to match your blood type. Your healthcare provider will do blood tests to match your blood type before you start treatment with SARCLISA. Tell all of your healthcare providers that you are being treated with SARCLISA before receiving blood transfusions.
Heart failure. Heart failure can happen during treatment with SARCLISA in combination with carfilzomib and dexamethasone. Tell your healthcare provider right away if you develop any of the following symptoms:
- — trouble breathing
- — cough
- — swelling of your ankles, feet, or legs

The most common side effects of SARCLISA in combination with pomalidomide and dexamethasone include:

lung infection (pneumonia)
decreased red blood cell counts (anemia)
upper respiratory tract infection
decreased platelet counts (thrombocytopenia)
diarrhea

The most common side effects of SARCLISA in combination with carfilzomib and dexamethasone include:

upper respiratory tract infection
tiredness and weakness
high blood pressure
diarrhea
lung infection (pneumonia)
trouble breathing
trouble sleeping
bronchitis
cough
back pain
decreased red blood cells (anemia)
decreased platelet counts (thrombocytopenia)

These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist.

Please see full Prescribing Information, including Patient Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

What is SARCLISA?

SARCLISA is a prescription medicine used in combination with:

The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment and they did not work or are no longer working.

It is not known if SARCLISA is safe and effective in children.

Please see full Prescribing Information, including Patient Information.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

This site is intended for US residents only.

Terms of Use
Privacy Policy
Site Map
Contact Us

SARCLISA, Sanofi, and Genzyme are registered in the U.S. Patent and Trademark Office.
© 2021 sanofi-aventis U.S. LLC. All rights reserved. MAT-US-2102498-v1.0-06/2021
Last updated: June 2021

Email a link to this page

Recipient's name*

Recipient's email address*

Your name*

Your email address*

Subject

Your friend has shared this page about highs and lows

send to another

Your email has been sent

Your email has been sent to:

×

Our commitment to patients during COVID-19

Sanofi CareASSIST may be able to help address your financial assistance concerns during COVID-19. We understand that you may have concerns about paying for your treatment. If you experience a change or loss in coverage, Sanofi CareASSIST may be able to help. You can call 1-833-WE+CARE (1-833-930-2273), and a Patient Access Specialist will review your specific eligibility during this time. Please click here.

To learn about the Sanofi response to COVID-19, please click here.

MAT-US-2013603 07/20

×

NOW FDA APPROVED
A NEW TREATMENT OPTION

Read the official press release and
talk with your doctor to learn more.

Our website will be updated soon with more information.
Download the SARCLISA Prescribing Information.

MAT-US-2102165-v1.0-03/2021

layer-1

This information is intended for US Healthcare Professionals only.

Select the “Continue” button below to go to the page you requested, or the “Cancel” button to return to the previous page.

layer-1

You are about to leave SARCLISA.com.

Sanofi Genzyme does not review or control the content of non–Sanofi Genzyme websites, and this hyperlink does not constitute an endorsement by Sanofi Genzyme of the site's content. Sanofi Genzyme's privacy procedures do not apply to the owners of a non–Sanofi Genzyme website.

You are about to leave sanofi site for U.S.

Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

This site might not comply with the regulatory requirements of US

You are about to move to an Unbranded site

You are moving to an Unbranded site